Literature DB >> 25517595

Aeromonas species: an opportunistic enteropathogen in patients with inflammatory bowel diseases? A single center cohort study.

Triana Lobatón1, Ilse Hoffman, Severine Vermeire, Marc Ferrante, Jan Verhaegen, Gert Van Assche.   

Abstract

BACKGROUND: The role of Aeromonas species as an enteropathogen in patients with and without inflammatory bowel disease (IBD) is still debated. The aim was to explore the significance of positive Aeromonas stool cultures in IBD and patients without IBD.
METHODS: Observational retrospective study including all patients with a stool culture positive for Aeromonas between January 2011 and October 2013 at the Leuven University Hospitals. Demographics, clinical, and endoscopic outcomes and laboratory results were analyzed.
RESULTS: A total of 77 patients (11 IBD) were identified. In 37 cases, Aeromonas caused a mild self-limited gastrointestinal infection. Among the 40 patients needing antibiotics, 22 presented a mild-to-moderate gastrointestinal infection; 4 suffered from extraintestinal complications; and 4 were coinfected by Campylobacter spp. A. veronii caused more frequently severe infection than the other species (25% versus 5%; P = 0.046). In 2 patients with ulcerative colitis, Aeromonas triggered a moderate-to-severe flare and 2 cases appeared in the context of de novo Crohn's disease. In contrast, in 1 patient with ulcerative colitis and 2 patients with Crohn's disease, Aeromonas caused a mild gastrointestinal infection not worsening the disease activity and in 4 patients with Crohn's disease, it presented in the context of active disease with no clear pathogenic role. Patients with IBD were treated more often with antibiotics (82 versus 41%, P = 0.012) and had more complications (46 versus 14%, P = 0.024).
CONCLUSIONS: Aeromonas caused mostly mild infections but also moderate and severe infections. A. veronii was more prevalent in patients with IBD and was associated with worse clinical outcomes. Aeromonas caused milder infections in patients without IBD. Other risk factors for severe infection were not found.

Entities:  

Mesh:

Year:  2015        PMID: 25517595     DOI: 10.1097/MIB.0000000000000247

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  5 in total

1.  Campylobacter jejuni and Pseudomonas coinfection in the setting of ulcerative colitis.

Authors:  John Paul Iguidbashian; Jai D Parekh; Shweta Kukrety; Venkata Giri Andukuri
Journal:  BMJ Case Rep       Date:  2018-06-06

2.  Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.

Authors:  Muhammad B Hammami; Ryan Gill; Nikhil Thiruvengadam; David Y Oh; Kendall Beck; Uma Mahadevan; Michael G Kattah
Journal:  Dig Dis Sci       Date:  2019-03       Impact factor: 3.199

3.  Clinical significance and outcome of Aeromonas spp. infections among 204 adult patients.

Authors:  J Nolla-Salas; J Codina-Calero; S Vallés-Angulo; A Sitges-Serra; A Zapatero-Ferrándiz; M C Climent; J Gómez; J R Masclans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-03-03       Impact factor: 3.267

4.  Analysis of global Aeromonas veronii genomes provides novel information on source of infection and virulence in human gastrointestinal diseases.

Authors:  Fang Liu; Christopher Yuwono; Alfred Chin Yen Tay; Michael C Wehrhahn; Stephen M Riordan; Li Zhang
Journal:  BMC Genomics       Date:  2022-02-28       Impact factor: 3.969

5.  Challenges in the diagnosis of ulcerative colitis with concomitant bacterial infections and chronic infectious colitis.

Authors:  Wei-Chen Lin; Chen-Wang Chang; Ming-Jen Chen; Cheng-Hsin Chu; Shou-Chuan Shih; Tzu-Chi Hsu; Horng-Yang Wang
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.